The prevalence of transmitted drug resistance in newly diagnosed HIV-infected individuals in Croatia: The role of transmission clusters of men who have sex with men carrying the T215S surveillance drug resistance mutation

AIDS Research and Human Retroviruses

Volumn 29, Issue 2, 2013, Pages 329-336

  Grgic, Ivana ^a   Lepej, Snjezana Zidovec ^a   Lunar, Maja M ^b   Poljak, Mario ^b   Vince, Adriana ^a   Vrakela, Ivana Baca ^a   Planinic, Ana ^a   Seme, Katja ^b   Begovac, Josip ^a  

^a Ministarstva Zdravstva i Socijalne Skrbi RH   (Croatia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; CROATIA; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; TRANSMITTED DRUG RESISTANCE; VIREMIA; VIRUS GENOME; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; CLUSTER ANALYSIS; CROATIA; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HOMOSEXUALITY, MALE; HUMANS; MALE; MOLECULAR EPIDEMIOLOGY; MUTATION, MISSENSE; PREVALENCE; SEQUENCE ANALYSIS, DNA;

EID: 84872972761     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0191     Document Type: Article

References (52)

1. Croatian Bureau of Statistics: Census of Population, Households and Dwellings 2011, First results by Settlements, http://www.dzs.hr (accessed August 29, 2011).
2. Begovac J, Zekan A, and Skoko-Poljak D: Twenty years of human immunodeficiency virus infection in CroatiaYan epidemic that is still in an early stage. Coll Antropol 2006;30:17-23.
3. Croatian National Institute of Public Health: Epidemiology of HIV infection and AIDS in Croatia. http://www.hzjz.hr/epidemiologija/hiv.htm (accessed August 29, 2011).
4. Bozicevic I and Begovac J: The emerging HIV epidemic among men who have sex with men in southeastern Europe. Expert Rev Anti Infect Ther 2010;8:1351-1358.
5. Romih V, Z idovec Lepej S, Gedike K, Lukas D, and Begovac J: Frequency of HIV-1 viral load monitoring of patients initially successfully treated with combination antiretroviral therapy. PLoS One 2010;5:e15051.
6. Ramirez-Piedad MK, Lepej SZ, Yerly S, and Begovac J: High prevalence of non-B HIV-1 subtypes in seamen and their sexual partners in Croatia. J Med Virol 2009;81:573-577.
7. Bo-zi-cević I, Rode OD, Lepej SZ, et al.: Prevalence of sexually transmitted infections among men who have sex with men in Zagreb, Croatia. AIDS Behav 2009;13:303-309.
8. Lepej SZ, Vrakela IB, Poljak M, Bozicevic I, and Begovac J: Phylogenetic analysis of HIV sequences obtained in a respondent-driven sampling study of men who have sex with men. AIDS Res Hum Retroviruses 2009;25:1335-1338.
9. Johnson VA, Brun-Vézinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010;18:156-163.
10. Bennett DE, Camacho RJ, Otelea D, et al.: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009;4:e4724.
11. Jørgensen LB, Christensen MB, Gerstoft J, et al.: Prevalence of drug resistance mutations and non-B subtypes in newly diagnosed HIV-1 patients in Denmark. Scand J Infect Dis 2003;35:800-807. (Pubitemid 38028914)
12. Paraskevis D, Magiorkinis E, Katsoulidou A, et al.: Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in Greece. Virus Res 2005;112:115-122. (Pubitemid 40966783)
13. Cane P, Chrystie I, Dunn D, et al.: Time trends in primary resistance to HIV drugs in the United Kingdom: Multicentre observational study. BMJ 2005;331:1368.
14. Ciccozzi M, Gori C, Boros S, et al.: Molecular diversity of HIV in Albania. J Infect Dis 2005;192:475-479. (Pubitemid 41023126)
15. Babic DZ, Zelnikar M, Seme K, et al.: Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-nai?ve patients in Slovenia, 2000-2004. Virus Res 2006;118:156-163.
16. Sagir A, Oette M, Kaiser R, et al.: Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother 2007;60:843-848. (Pubitemid 47434265)
17. Paraschiv S, Otelea D, Dinu M, Maxim D, and Tinischi M: Polymorphisms and resistance mutations in the protease and reverse transcriptase genes of HIV-1 F subtype Romanian strains. Int J Infect Dis 2007;11:123-128.
18. Bannister WP, Cozzi-Lepri A, Clotet B, et al.: Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. J Acquir Immune Defic Syndr 2008; 48:324-333.
19. Vercauteren J, Derdelinckx I, Sasse A, et al.: Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res Hum Retroviruses 2008;24:355-362. (Pubitemid 351457751)
20. Vercauteren J, Deforche K, Theys K, et al.: The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology 2008;5:12.
21. Santoro MM, Ciccozzi M, Alteri C, et al.: Characterization of drug-resistance mutations in HIV type 1 isolates from drugnaive and ARV-treated patients in Bulgaria. AIDS Res Hum Retroviruses 2008;24:1133-1138.
22. Madsen TV, Lohse N, Jensen ES, et al.: High prevalence of drug-resistant human immunodeficiency virus type 1 in treatment-nai?ve patients in Greenland. AIDS Res Hum Retroviruses 2008;24:1073-1077.
23. Chaix ML, Descamps D, Wirden M, et al.: Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 2009; 23:717-724.
24. Yerly S, Junier T, Gayet-Ageron A, et al.: The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS 2009;23:1415-1423.
25. Avi R, Huik K, Sadam M, et al.: Absence of genotypic drug resistance and presence of several naturally occurring polymorphisms of human immunodeficiency virus-1 CRF06-cpx in treatment-naive patients in Estonia. J Med Virol 2009;81:953-958.
26. Stań czak GP, Stań czak JJ, Marczyń ska M, et al.: Evolving patterns of HIV-1 transmitted drug resistance in Poland in the years 2000-2008. J Med Virol 2010;82:1291-1294.
27. Bonura F, Tramuto F, Vitale F, Perna AM, Viviano E, Romano N; Group for HIV-1 Antiretroviral Studies in Sicily: Transmission of drug-resistant HIV type 1 strains in HAART-naive patients: A 5-year retrospective study in Sicily, Italy. AIDS Res Hum Retroviruses 2010;26:961-965.
28. Riva C, Lai A, Caramma I, et al.: Transmitted HIV Type 1 drug resistance and Non-B subtypes prevalence among seroconverters and newly diagnosed patients from 1992 to 2005 in Italy. AIDS Res Hum Retroviruses 2010 ;26:41-49.
29. Mezei M, Ay E, Koroknai A, et al.: Molecular epidemiological analysis of env and pol sequences in newly diagnosed HIV Type 1-infected, untreated patients in Hungary. AIDS Res Hum Retroviruses 2011;27(11):1243-1247.
30. Yebra G, De Mulder M, del Romero J, Rodríguez C, and Holguín A: HIV-1 non-B subtypes: High transmitted NNRTI-resistance in Spain and impaired genotypic resistance interpretation due to variability. Antiviral Res 2010; 85:409-417.
31. Audelin AM, Gerstoft J, Obel N, et al.: Molecular phylogenetics of transmitted drug resistance in newly diagnosed HIV type 1 individuals in Denmark, a nation-wide study. AIDS Res Hum Retroviruses 2011;27:1-8.
32. Vercauteren J, Wensing AM, van De Vijver DA, et al.: Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009;200:1503-1508.
33. Ciccozzi M, Vujosević D, Lo Presti A, et al.: Genetic diversity of HIV type 1 in Montenegro. AIDS Res Hum Retroviruses 2011;27:921-924.
34. De Oliveira T, Deforche K, Cassol S, et al.: An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2009;4:e4724.
35. Hall TA: BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 1999;41:95-98.
36. Guindon S, Dufayard J-F, Lefort V, et al.: New algorithms and methods to estimate maximum-likelihood phylogenies: Assessing the performance of PhyML 3.0. Syst Biol 2010;59:307-321.
37. Posada D: jModelTest: Phylogenetic model averaging. Mol Biol Evol 2008;25:1253-1256. (Pubitemid 351882013)
38. Guindon S and Gascuel O: A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 2003;52:696-704. (Pubitemid 37365050)
39. Huelsenbeck JP and Ronquist F: MRBAYES: Bayesian inference of phylogenetic trees. Bioinformatics 2001;17:754-755. (Pubitemid 32851390)
40. Ronquist F and Huelsenbeck JP: MrBayes 3: Bayesian phylogenetic inference under mixed models. Bioinformatics 2003;19:1572-1574. (Pubitemid 37038874)
41. Huson DH, Scornavacca C: Dendroscope 3: An interactive viewer for rooted phylogenetic trees and networks. Syst Biol 2012 [Epub ahead of print]; DOI: 10.1093/sysbio/sys062.
42. Chalmet K, Staelens D, Blot S, et al.: Epidemiological study of phylogenetic transmission clusters in a local HIV-1 epidemic reveals distinct differences between subtype B and non-B infections. BMC Infect Dis 2010;10:262.
43. Johnson VA, Brun-Vézinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010;18:156-163.
44. Stanojevic M, Alexiev I, Beshkov D, et al.: HIV-1 molecular epidemiology in the BalkansYa melting pot for high genetic diversity. AIDS Rev 2012;14:28-36.
45. Giuliani M, Montieri S, Palamara G, et al.: Non-B HIV type 1 subtypes among men who have sex with men in Rome, Italy. AIDS Res Hum Retroviruses 2009;25:157-164.
46. Chilton DN, Castro H, Lattimore S, et al.: HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Antivir Ther 2010;15:985-991.
47. Fox J, Hill S, Kaye S, et al.: Prevalence of primary genotypic resistance in a UK centre: Comparison of primary HIV-1 and newly diagnosed treatment-naive individuals. AIDS 2007; 21:237-239. (Pubitemid 46036933)
48. Booth CL, Garcia-Diaz AM, Youle MS, Johnson MA, Phillips A, and Geretti AM: Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 2007;59:517-524. (Pubitemid 47073459)
49. Maphalala G, Okello V, Mndzebele S, et al.: Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006. Antivir Ther 2008;13(Suppl 2):95-100. (Pubitemid 352019095)
50. Kamoto K and Aberle-Grasse J; Malawi HIV Drug Resistance Task Force: Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther 2008;13(Suppl 2):83-87. (Pubitemid 352019093)
51. Somi GR, Kibuka T, Diallo K, et al.: Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther 2008;13(Suppl 2):77-82. (Pubitemid 352019092)
52. Pillay V, Ledwaba J, Hunt G, et al.: Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008;13(Suppl 2):101-107. (Pubitemid 352019096)